Aigen Investment Management, LP Incyte Corp Transaction History

Aigen Investment Management, LP

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$56.55 - $66.59 $118,132 - $139,106	-2,089 Reduced 24.57%	6,414 $365,000
Q4 2023 Feb 09, 2024	SELL	$52.16 - $64.19 $114,282 - $140,640	-2,191 Reduced 20.49%	8,503 $533,000
Q3 2023 Nov 13, 2023	SELL	$57.77 - $65.93 $3.6 Million - $4.11 Million	-62,296 Reduced 85.35%	10,694 $617,000
Q2 2023 Aug 14, 2023	BUY	$60.95 - $75.51 $4.45 Million - $5.51 Million	72,990 New	72,990 $4.54 Million
Q4 2022 Feb 10, 2023	BUY	$67.18 - $84.11 $4.81 Million - $6.02 Million	71,552 New	71,552 $5.75 Million
Q4 2021 Feb 11, 2022	SELL	$63.34 - $74.11 $1.36 Million - $1.59 Million	-21,494 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$68.67 - $84.02 $3.48 Million - $4.25 Million	-50,634 Reduced 70.2%	21,494 $1.48 Million
Q2 2021 Aug 10, 2021	BUY	$79.87 - $87.53 $3.56 Million - $3.9 Million	44,560 Added 161.64%	72,128 $6.07 Million
Q1 2021 May 11, 2021	BUY	$76.02 - $100.5 $1.56 Million - $2.06 Million	20,467 Added 288.23%	27,568 $2.24 Million
Q4 2020 Feb 12, 2021	BUY	$80.74 - $97.7 $308,103 - $372,823	3,816 Added 116.16%	7,101 $618,000
Q3 2020 Nov 06, 2020	SELL	$85.07 - $109.69 $418,714 - $539,894	-4,922 Reduced 59.97%	3,285 $295,000
Q2 2020 Aug 10, 2020	SELL	$74.18 - $108.93 $452,572 - $664,581	-6,101 Reduced 42.64%	8,207 $853,000
Q1 2020 May 08, 2020	BUY	$63.18 - $85.97 $822,098 - $1.12 Million	13,012 Added 1004.01%	14,308 $1.05 Million
Q4 2019 Feb 04, 2020	BUY	$73.04 - $95.72 $94,659 - $124,053	1,296 New	1,296 $113,000

657

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.5B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Aigen Investment Management, LP, based on Form 13F filings with the SEC.

Stay updated on Aigen Investment Management, LP with notifications on news.